Arrowhead Pharmaceuticals (ARWR) Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends.

Which has more volatility & risk, ASND or ARWR?

Ascendis Pharma A/S has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Does the media refer more to ASND or ARWR?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 5 mentions for Arrowhead Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.69 beat Arrowhead Pharmaceuticals' score of 0.44 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	0 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is ASND or ARWR more profitable?

Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -130.33%. Ascendis Pharma A/S's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-130.33%	N/A	-48.77%
Arrowhead Pharmaceuticals	N/A	-182.69%	-64.04%

Which has higher valuation and earnings, ASND or ARWR?

Ascendis Pharma A/S has higher revenue and earnings than Arrowhead Pharmaceuticals. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$327.43M	23.75	-$521.07M	-$8.08	-15.86
Arrowhead Pharmaceuticals	$3.55M	685.59	-$599.49M	-$5.02	-3.90

Do analysts rate ASND or ARWR?

Ascendis Pharma A/S presently has a consensus price target of $192.07, suggesting a potential upside of 49.90%. Arrowhead Pharmaceuticals has a consensus price target of $43.33, suggesting a potential upside of 121.54%. Given Arrowhead Pharmaceuticals' higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93
Arrowhead Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

Do insiders & institutionals believe in ASND or ARWR?

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 4.5% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer ASND or ARWR?

Arrowhead Pharmaceuticals received 104 more outperform votes than Ascendis Pharma A/S when rated by MarketBeat users. However, 66.57% of users gave Ascendis Pharma A/S an outperform vote while only 65.31% of users gave Arrowhead Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Ascendis Pharma A/S	Outperform Votes 440 66.57%	Underperform Votes 221 33.43%
Arrowhead Pharmaceuticals	Outperform Votes 544 65.31%	Underperform Votes 289 34.69%

Summary

Ascendis Pharma A/S beats Arrowhead Pharmaceuticals on 10 of the 18 factors compared between the two stocks.